Labcorp Holdings Inc. $LH Shares Acquired by Everett Harris & Co. CA

Everett Harris & Co. CA lifted its position in shares of Labcorp Holdings Inc. (NYSE:LH) by 10.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 38,003 shares of the medical research company’s stock after buying an additional 3,722 shares during the quarter. Everett Harris & Co. CA’s holdings in Labcorp were worth $9,534,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in Labcorp during the 4th quarter worth about $26,000. Hilton Head Capital Partners LLC purchased a new stake in Labcorp during the 4th quarter worth about $27,000. JPL Wealth Management LLC purchased a new stake in Labcorp during the 3rd quarter worth about $28,000. Eagle Bay Advisors LLC purchased a new stake in Labcorp during the 4th quarter worth about $29,000. Finally, Beacon Financial Strategies CORP purchased a new stake in Labcorp during the 4th quarter worth about $33,000. Institutional investors and hedge funds own 95.94% of the company’s stock.

Labcorp Stock Down 1.3%

LH opened at $261.67 on Tuesday. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.73 and a quick ratio of 1.54. The stock has a market capitalization of $21.46 billion, a price-to-earnings ratio of 23.18, a price-to-earnings-growth ratio of 1.86 and a beta of 0.90. The business has a 50-day moving average of $262.61 and a two-hundred day moving average of $265.66. Labcorp Holdings Inc. has a 12 month low of $241.81 and a 12 month high of $293.72.

Labcorp (NYSE:LH) last posted its quarterly earnings results on Thursday, April 30th. The medical research company reported $4.25 EPS for the quarter, beating the consensus estimate of $4.09 by $0.16. The company had revenue of $3.54 billion during the quarter, compared to analysts’ expectations of $3.51 billion. Labcorp had a return on equity of 16.29% and a net margin of 6.66%.The firm’s revenue was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.84 EPS. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. On average, research analysts expect that Labcorp Holdings Inc. will post 18 earnings per share for the current year.

Labcorp Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 11th. Shareholders of record on Friday, May 29th will be issued a $0.72 dividend. The ex-dividend date is Friday, May 29th. This represents a $2.88 annualized dividend and a yield of 1.1%. Labcorp’s payout ratio is 25.51%.

Wall Street Analyst Weigh In

A number of research firms recently commented on LH. Morgan Stanley reiterated an “overweight” rating on shares of Labcorp in a research report on Tuesday, February 17th. Evercore reiterated an “outperform” rating and set a $300.00 price objective on shares of Labcorp in a research report on Wednesday, April 8th. Wall Street Zen upgraded Labcorp from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Robert W. Baird set a $334.00 price objective on Labcorp in a research report on Friday, May 1st. Finally, JPMorgan Chase & Co. lifted their price objective on Labcorp from $319.00 to $330.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 18th. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $308.00.

Insider Buying and Selling

In other Labcorp news, CEO Adam H. Schechter sold 5,903 shares of Labcorp stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $254.50, for a total value of $1,502,313.50. Following the completion of the sale, the chief executive officer owned 107,234 shares in the company, valued at $27,291,053. The trade was a 5.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.84% of the stock is owned by company insiders.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.